Global Single-Cell Analysis Market to Grow at a CAGR of 14.5% During 2021-2026, Driven by Increasing Investments in Cancer Research

The rapid development of healthcare infrastructure, technological advances in single-cell analysis tools, increased investments in cancer research, and a rise in the biotechnology and biopharmaceutical businesses have stimulated the market growth in North America. The rising incidence of chronic diseases and public awareness has also increased diagnostic research. The studied market is projected to have good growth potential during the pandemic period, as evidenced by the adoption of the single-cell analysis technique in the SARS-CoV2 virus investigation.

In July 2021, Thermo Fisher Scientific (NYSE: TMO), one of the leading key players, designed Ion Torrent Oncomine immune repertoire assays to detect potentially cancerous clones of T-cells and B-cells, which play a critical part in the immune response system. The new pan-clonality assays use unique Ion AmpliSeq technology to target several sections of the B- and T-cell immune receptors in a single reaction with ultra-high sensitivity, boosting the likelihood of malignant clone detection and reducing time for the results. This is expected to quickly provide researchers with a wealth of information about a lymphoid cancer sample, including its prevalence and how it is changing. Such developments are anticipated to propel the growth of the single-cell analysis industry in the forecast period.

Market Analysis by Product, Application, Workflow, End-Use, and Region:

• The market, on the basis of product, can be divided into consumables and instruments.
• Based on application, the industry can be divided into cancer, immunology, neurology, stem cell, non-invasive prenatal diagnosis, and in-vitro fertilisation, among others.
• The workflows for the industry include single-cell isolation and library, downstream analysis, and data analysis.
• Based on end-use, the industry can be divided into academic and research laboratories, biotechnology and pharmaceutical companies, hospitals and diagnostics laboratories, among others.
• The regional markets for the market include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

Key Findings of the Report:

• The rising incidence of cancer has increased investments in cancer research. This is expected to boost the market for single-cell analysis.
• The application of single-cell analysis in virology sky-rocketed during the SARS-CoV2 virus investigation and is expected to grow throughout the pandemic. This is expected to bolster the market growth over the forecast period.
• The rising health awareness has pushed the demand for early diagnosis among the masses. The growing research attempts are being made to cater to the needs of the population, consequently augmenting the market growth.
• The market has been boosted by the rapid development of healthcare infrastructure, technological advancements in single-cell analysis techniques, and a rise in the biotechnology and biopharmaceutical industries.
• Falling cost of genome sequencing is also a major driver of the market.

Key Offerings of the Report:

• The EMR report gives an overview of the global single-cell analysis market for the periods (2016-2020) and (2021-2026).
• The report also offers the historical (2016-2020) and forecast (2021-2026) markets for the product, application, workflow, end-use, and regions of single-cell analysis.
• The report analyses the market dynamics, covering the key demand and price indicators in the market, along with an assessment of the SWOT and Porter’s Five Forces models.

The major players in the global market for single-cell analysis are Thermo Fisher Scientific, Inc., QIAGEN N.V., Bio-Rad Laboratories, Inc., Illumina, Inc., Becton, and Dickinson and Company, among others. The comprehensive report by EMR looks into the market share, capacity, and latest developments like mergers and acquisitions, plant turnarounds, and capacity expansions of the major players.

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.